PMID: 25764677Mar 15, 2015Paper

Development of the novel oral vaccine against hepatitis C virus utilizing bifidobacteria

Nihon rinsho. Japanese journal of clinical medicine
Toshiro Shirakawa

Abstract

Approximately 3% of the world people have chronically infected with hepatitis C virus (HCV), and about 30% of those will develop progressive liver disease, such as cirrhosis and hepatocellular carcinoma. The current standard treatment for HCV of a combination of pegylated interferon-α with ribavirin and the development of new direct-acting antiviral agents, have dramatically improved the virus eradication rate. However those treatments have some toxicities and too expensive to be applied in developing countries, where have high HCV infection rates. Therefore there is a still great need to develop the novel vaccines, which can protect or treat HCV infection with the high efficacies and low adverse effects and costs. Currently we are developing the novel oral vaccine against HCV utilizing bifidobacteria.

Related Concepts

Related Feeds

Carcinoma, Hepatocellular

Hepatocellular Carcinoma is a malignant cancer in liver epithelial cells. Discover the latest research on Hepatocellular Carcinoma here.

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.